Keyword: Bristol-Myers Squibb
The cost of new cancer drug rollouts—$200,000 on average last year—is helping drive treatment costs toward $100 billion annually in the U.S. alone.
Don't dismiss Trump's move to put drug prices in DTC ads. Five senators wrote top execs urging them to do it voluntarily or face congressional action.
Portola has won FDA approval of Andexxa, its antidote for some next-gen bloodthinners, but a manufacturing upgrade will limit initial supplies.
Top drugmakers made more trips to the courthouse last year, aiming to blockade big-selling drugs against generic competitors.
BMS may face questions about how its I-O drug Opdivo will compete with Merck’s rival in lung cancer‚ but meanwhile, the drug’s bringing home the bacon.
It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.
Merck needed a big win in melanoma to help it try to catch up to archrival Bristol-Myers Squibb. And over the weekend, it got one.
In February, BMS tallied a lung cancer win for its immuno-oncology combo. But one question remained: Was the win big enough to keep it competitive?